| |
Analysis 1
|
Analysis 2
|
Analysis 3
|
|---|
|
Pre-treatment, n = 103
|
Control, n = 39
|
p value
|
Pre-treatment, n = 103
|
Post-treatment, n = 103
|
p value
|
Post-treatment, n = 103
|
Control, n = 39
|
p value
|
|---|
|
Age, years
| | |
0.0573
| | |
0.4131
| | |
0.0130
|
|
Mean (SD, range)
|
31.9 (5.2, 25–45)
|
30.1 (4.4, 20–43)
| |
31.9 (5.2, 25–45)
|
32.5 (5.3, 25–46)
| |
32.5 (5.3, 25–46)
|
30.1 (4.4, 20–43)
| |
|
Ethnicity, n/N (%)
| | |
0.0659
| | |
> 0.9999
| | |
0.0659
|
|
Caucasian
|
87/103 (85)
|
30/39 (77)
| |
87/103 (85)
|
87/103 (85)
| |
87/103 (85)
|
30/39 (77)
| |
|
Asian
|
10/103 (10)
|
2/39 (5)
| |
10/103 (10)
|
10/103 (10)
| |
10/103 (10)
|
2/39 (5)
| |
|
Black
|
6/103 (5)
|
7/39 (18)
| |
6/103 (5)
|
6/103 (5)
| |
6/103 (5)
|
7/39 (18)
| |
|
Parity, n/N (%)
| | |
0.5329
| | |
> 0.9999
| | |
0.5329
|
|
Nulliparous
|
73/103 (71)
|
30/39 (76)
| |
73/103 (71)
|
73/103 (71)
| |
73/103 (71)
|
30/39 (76)
| |
|
Parous
|
30/103 (29)
|
9/39 (24)
| |
30/103 (29)
|
30/103 (29)
| |
30/103 (29)
|
9/39 (24)
| |
|
Smoking status, n/N (%)
| | |
0.1909
| | |
> 0.9999
| | |
0.2647
|
|
Current smoker
|
27/103 (26)
|
6/39 (15)
| |
27/103 (26)
|
26/103 (25)
| |
26/103 (25)
|
6/39 (15)
| |
|
Non-smoker
|
76/103 (74)
|
33/39 (85)
| |
76/103 (74)
|
77/103 (75)
| |
77/103 (75)
|
33/39 (85)
| |
|
Phase of menstrual cycle, n/N (%)
| | |
0.6472
| | |
0.4655
| | |
0.5388
|
|
Luteal
|
55/103 (53)
|
23/39 (58)
| |
55/103 (53)
|
50/103 (48)
| |
50/103 (48)
|
23/39 (58)
| |
|
Follicular
|
38/103 (37)
|
14/39 (36)
| |
38/103 (37)
|
46/103 (46)
| |
46/103 (46)
|
14/39 (36)
| |
|
Unknown
|
10/103 (10)
|
2/39 (5)
| |
10/103 (10)
|
7/103 (7)
| |
7/103 (7)
|
2/39 (5)
| |
|
Contraception, n/N (%)
| | |
0.7316
| | |
0.9982
| | |
0.6958
|
|
Nil
|
35/103 (34)
|
19/39 (49)
| |
35/103 (34)
|
34/103 (33)
| |
34/103 (33)
|
19/39 (49)
| |
|
Condoms
|
17/103 (16)
|
5/39 (13)
| |
17/103 (16)
|
18/103 (17)
| |
18/103 (17)
|
5/39 (13)
| |
|
COCP
|
37/103 (36)
|
12/39 (31)
| |
37/103 (36)
|
37/103 (36)
| |
37/103 (36)
|
12/39 (31)
| |
|
POP
|
5/103 (5)
|
1/39 (2)
| |
5/103 (5)
|
5/103 (5)
| |
5/103 (5)
|
1/39 (2)
| |
|
Copper IUD
|
2/103 (2)
|
0/39 (0)
| |
2/103 (2)
|
1/103 (1)
| |
1/103 (1)
|
0/39 (0)
| |
|
Mirena IUS
|
5/103 (5)
|
1/39 (2)
| |
5/103 (5)
|
6/103 (6)
| |
6/103 (6)
|
1/39 (2)
| |
|
Contraceptive implant
|
2/103 (2)
|
1/39 (2)
| |
2/103 (2)
|
2/103 (2)
| |
2/103 (2)
|
1/39 (2)
| |
|
Time since last intercourse, n/N (%)
| | |
0.7684
| | |
> 0.9999
| | |
0.7684
|
|
> 48 h
|
92/103 (89)
|
34/39 (87)
| |
92/103 (89)
|
92/103 (89)
| |
92/103 (89)
|
34/39 (87)
| |
|
< 48 h
|
11/103 (11)
|
5/39 (13)
| |
11/103 (11)
|
11/103 (11)
| |
11/103 (11)
|
5/39 (13)
| |
|
HPV status
| | |
–
|
–
| |
–
|
–
| |
–
|
|
Negative
|
–
|
–
| |
–
|
–
| |
82/103 (80)
|
23/39 (59)
| |
|
Positive
|
–
|
–
| |
–
|
–
| |
21/103 (20)
|
12/39 (31)
| |
|
Unknown
|
–
|
–
| |
–
|
–
| |
0/103 (0)
|
4/39 (10)
| |
|
Cytology
| | | | | | | | | |
|
Negative
|
–
|
–
| |
–
|
–
| |
81/103 (79)
|
39/39 (100)
| |
|
Borderline nuclear changes
|
–
|
–
| |
–
|
–
| |
17/103 (16)
|
0/39 (0)
| |
|
LSIL
|
–
|
–
| |
–
|
–
| |
3/103 (3)
|
0/39 (0)
| |
|
HSIL
|
–
|
–
| |
–
|
–
| |
2/103 (2)
|
0/39 (0)
| |
|
Cytology and HPV status
| | |
–
|
–
| |
–
|
–
| |
–
|
|
Normal, HPV-ve
|
–
|
–
| |
–
|
–
| |
70/103 (69)
|
23/39 (59)
| |
|
Normal, HPV+ve
|
–
|
–
| |
–
|
–
| |
11/103 (10)
|
12/39 (31)
| |
|
Normal, HPV status unknown
|
–
|
–
| |
–
|
–
| |
0/103 (0)
|
4/39 (10)
| |
|
BNC, HPV-ve
|
–
|
–
| |
–
|
12/103 (11)
| |
12/103 (11)
|
0/39 (0)
| |
|
BNC, HPV+ve
|
–
|
–
| |
–
|
5/103 (5)
| |
5/103 (5)
|
0/39 (0)
| |
|
LSIL, HPV-ve
|
–
|
–
| |
–
|
0/103 (0)
| |
0/103 (0)
|
0/39 (0)
| |
|
LSIL, HPV+ve
|
–
|
–
| |
–
|
3/103 (3)
| |
3/103 (3)
|
0/39 (0)
| |
|
HSIL
|
–
|
–
| |
–
|
2/103 (2)
| |
2/103 (2)
|
0/39 (0)
| |
- BNC borderline nuclear changes, CIN cervical intraepithelial neoplasia, COCP combined oral contraceptive pill, HSIL high-grade squamous intraepithelial neoplasia, HPV human papillomavirus, IUD intrauterine device, IUS intrauterine system, LSIL low-grade squamous intraepithelial neoplasia, POP progesterone-only pill, SD standard deviation
